Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigecycline vs Ampicillin-Sulbactam or Amoxicillin-Clavulanate in Complicated Skin and Skin Structure Infections
NCT00368537Phase 4Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Sep 2008
- Modality
- Orthosteric Ligands
- Countries
- 12
01
Overview
Phase 4, randomised, open-label trial of tigecycline in Complicated skin and skin structure infection (cSSSI) (2 arms), sponsored by Pfizer. Primary endpoint: Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure up to 6 weeks. Started Sep 2006; status: completed.
02
Drugs
tigecycline
03
Conditions
Complicated skin and skin structure infection (cSSSI)
Beyond the preview
Go deeper on NCT00368537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368537.